Skip to content

Analgesic Effect of Music Listening During Pain Elicitation in Fibromyalgia

Analgesic Effect of Music Listening During Pain Elicitation in Fibromyalgia

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04059042
Acronym
FMMusic
Enrollment
10
Registered
2019-08-16
Start date
2019-12-13
Completion date
2020-03-23
Last updated
2023-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia

Keywords

Pain, Music, Analgesia

Brief summary

Patients with fibromyalgia (FM) are more sensitive to things that cause pain. Music lowers self-reported pain in patients with chronic pain. The investigators are able to measure pain sensitivity and pain tolerance using tools that cause pain and give accurate measurements of how much pressure is put on the body (QST). Previous studies have shown that after a few minutes of listening to music patients with FM have less self-reported pain, can get up and move from sitting more quickly, and have more activity in part of the brain that tells the body to stop sending pain signals. The investigators will study 40 patients with FM using the QST tools. All patients will have testing done as usual, with no sound. Then half of the patients will have testing done while listening to instrumental Classical music, and the other half will have testing done while listening to nature sounds. The investigators will test 1) whether listening to anything lessens pain compared to listening to nothing at all; and 2) whether listening to music lessens pain more than listening to nature sounds. Our study will be the first to study whether objectively measured pain sensitivity is less while listening to music in these patients.

Detailed description

Fibromyalgia can be thought of as a centralized pain state where pain is manifested and experienced in different body regions at different times. Individuals with centralized pain feel more pain than would be normally expected based on the level of nociceptive input. Music has previously been shown to have a positive effect on pain, anxiety, and depression in chronic pain patients. However, the impact of music listening on objective measures of pain sensitivity in patients with chronic pain have not yet been described. The goal of this pilot study is to begin to understand the possible analgesic effects of music listening on objective measures of pain sensitivity in patients with fibromyalgia. Previous studies in patients with FM have shown that patients have reduced self-reported pain, increased mobility, and activation of the descending pain modulatory system in the brain after even a short, 5 to10-minute music listening intervention. Our proposed study will be the first to investigate whether objectively measured pain sensitivity is reduced by music listening in these patients. This two-arm parallel randomized controlled pilot study will enroll 40 patients with fibromyalgia. Patients' pain thresholds and sensitivity will be measured using a battery of quantitative sensory tests (QST). All patients will have two testing sessions: one under testing as usual conditions with no-sound, and one while listening to either instrumental Classical music, selected by the researchers with careful consideration of the musical characteristics, or a nature sound placebo control condition. This careful experimental design will allow us to test whether music listening elicits greater analgesic effects over simple auditory distraction. To minimize potential bias the investigators will employ sound cancelling headphones and randomization of conditions so that the researcher collecting the QST measures will be blinded to whether the patient is hearing music, nature sounds, or nothing. The proposed study is significant as it will identify whether music listening has an analgesic effect during pain threshold and tolerance testing for patients with FM that supercedes any effect of auditory distraction. Results from the proposed study may provide objective evidence that music listening objectively improves analgesia and pain management and thus could be considered therapeutic during situations where acute pain is expected

Interventions

BEHAVIORALMusic Listening

Participants will have pain threshold testing while listening to silence, music, or nature sounds.

Sponsors

University of Kansas Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

Personnel who interact directly with the study subjects (either human or non-human subjects) will not be aware of the assigned treatments. (Commonly known as double blind) Personnel who analyze the data collected from the study are not aware of the treatment applied to any given group.

Intervention model description

Two-arm (Music, Nature Sounds) parallel randomized controlled pilot study in patients with fibromyalgia with between-subject counterbalanced repeated measure control (Silence). The primary outcome measure will be pain threshold and tolerance as measured by the quantitative sensory testing (QST) battery.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Ability to read and speak English to allow for written informed consent, phenotyping, and patient- reported outcomes measures * Willingness to refrain from alcohol and nicotine on day of QST * Willingness to refrain from physical activity or exercise that would cause muscle and/or joint soreness for 48 hours prior to testing (routine exercise or activity that does not lead to soreness is acceptable) * The investigators will attempt to recruit individuals with no chronic daily use of adjunctive pain medications, including tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, and gabapentinoids as these drugs can influence QST findings, or have individuals be weaned off of these meds at least two weeks prior to being studied. If the investigators do need to allow individuals into these cohorts while on such medications because of pragmatic issues, this information will be recorded and patients will be asked to remain on a stable dose for at least two weeks prior to QST assessments.

Exclusion criteria

* Individuals receiving or applying for compensation or disability and other aspects associated with potential secondary gain * Inability to provide written informed consent * Peripheral neuropathy or loss of sensation in the upper or lower extremities which would preclude QST testing * Severe physical impairment (e.g., blindness, deafness, paraplegia) * Co-morbid medical conditions that may significantly impair physical functional status (e.g., history of non- skin malignancy, or autoimmune disorder) * Illicit drug or unreported opioid use (unreported opioid use would be considered opioid abuse and thereby excluded) * Medical or psychiatric conditions that in the judgment of study personnel would preclude participation in this study (e.g., malignancy, psychosis, suicidal ideation) * Pregnant or nursing * Liver failure * Self-reported liver cirrhosis * Self-reported hepatitis * Severe Cardiovascular disease (examples: history of myocardial infarction, unstable angina, severe coronary artery disease, congestive heart failure, or severe valvular abnormalities) that are self-reported by patient or by medical record * Average daily opioid dosing of \>15 mg oral morphine equivalents preoperatively (e.g., \> two 5 mg oxycodone tablets/day or \> three 5 mg hydrocodone tablets/day). Conversions will be made based on well-accepted conversion tools used previously. The rationale to include some patients taking low dose opioids is to enhance the generalizability of the findings (opioids are common in patients with many pain states), while not causing confounding by including patients on very high doses of opioids which may be a cause of opioid induced hyperalgesia which closely resembles central sensitization

Design outcomes

Primary

MeasureTime frameDescription
Pain Threshold Summation1 weekPain threshold summation as measured by the quantitative sensory testing (QST) battery. Pain is rated subjectively on a 0-100 scale with 0 being no pain and 100 being the worst pain imaginable. Summation is calculated as the difference in pain score between a single stimulus and a series of 10 stimuli with larger values indicating more severe summation.
Pain Tolerance1 weekPain tolerance as measured by the quantitative sensory testing (QST) battery. Pain is rated subjectively on a 0-100 scale with 0 being no pain and 100 being the worst pain imaginable. Tolerance is the pressure (kg/cm2) at which participants rated pain in their non-dominant thumb at 70 out of 100.

Countries

United States

Participant flow

Participants by arm

ArmCount
Music
The investigators will manipulate the audio environment the participant experiences 10 minutes before and throughout pain threshold testing (\ 1 hour). All participants will have one testing session with silence (testing as usual control). On the other testing session, participants will hear music. The musical selections will be professional recordings of instrumental Classical music selected by the researcher. All participants will hear the same pieces in the same order. Instrumentation ranges from piano solo to full orchestra, but they are without lyrics or heavy percussion. Pitch ranges across the pieces, but is standard across participants and not controlled by either the participant or the researcher. Tempo for all of the pieces is slow (\ 60 beats per minute). The pieces are in either major keys or minor keys, but all consist primarily of consonant harmonies and sustained melodic phrases. Participants will control the volume to their individual comfort level. Music Listening: Participants will have pain threshold testing while listening to silence, music, or nature sounds.
4
Nature Sounds
The investigators will manipulate the audio environment the participant experiences 10 minutes before and throughout pain threshold testing (\ 1 hour). All participants will have one testing session with silence (testing as usual control). On the other testing session, participants will hear nature sounds. Professional recordings of nature sounds selected by the researcher without added music will be used as the active placebo control condition. All participants will hear the same recording. This active control condition will allow for non-musical analgesic effects, such as distraction, to be controlled in the experimental design. Participants will control the volume to their individual comfort level. Music Listening: Participants will have pain threshold testing while listening to silence, music, or nature sounds.
5
Total9

Baseline characteristics

CharacteristicNature SoundsTotalMusic
Age, Continuous40.28 years
STANDARD_DEVIATION 9.93
44.24 years
STANDARD_DEVIATION 11.97
49.18 years
STANDARD_DEVIATION 13.86
Dominant Hand - Right5 Participants9 Participants4 Participants
Education
Advanced/professional degree
1 Participants4 Participants3 Participants
Education
Bachelor's degree
2 Participants2 Participants0 Participants
Education
High school/GED
0 Participants0 Participants0 Participants
Education
Some College
1 Participants2 Participants1 Participants
Education
Technical/Associate's degree
1 Participants1 Participants0 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants1 Participants1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
5 Participants7 Participants2 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants1 Participants1 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
5 Participants9 Participants4 Participants
Region of Enrollment
United States
5 Participants9 Participants4 Participants
Sex/Gender, Customized
Female
5 Participants9 Participants4 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 50 / 5
other
Total, other adverse events
1 / 50 / 5
serious
Total, serious adverse events
0 / 50 / 5

Outcome results

Primary

Pain Threshold Summation

Pain threshold summation as measured by the quantitative sensory testing (QST) battery. Pain is rated subjectively on a 0-100 scale with 0 being no pain and 100 being the worst pain imaginable. Summation is calculated as the difference in pain score between a single stimulus and a series of 10 stimuli with larger values indicating more severe summation.

Time frame: 1 week

ArmMeasureGroupValue (MEAN)Dispersion
MusicPain Threshold SummationSilence20.17 units on a 100 point scaleStandard Deviation 13.14
MusicPain Threshold SummationAudio20.25 units on a 100 point scaleStandard Deviation 14.29
Nature SoundsPain Threshold SummationAudio4.13 units on a 100 point scaleStandard Deviation 5.6
Nature SoundsPain Threshold SummationSilence9.40 units on a 100 point scaleStandard Deviation 7.44
p-value: 0.0051Wilcoxon (Mann-Whitney)
p-value: 0.03Wilcoxon (Mann-Whitney)
Primary

Pain Tolerance

Pain tolerance as measured by the quantitative sensory testing (QST) battery. Pain is rated subjectively on a 0-100 scale with 0 being no pain and 100 being the worst pain imaginable. Tolerance is the pressure (kg/cm2) at which participants rated pain in their non-dominant thumb at 70 out of 100.

Time frame: 1 week

ArmMeasureGroupValue (MEAN)Dispersion
MusicPain ToleranceAudio4.12 kg/cm2Standard Deviation 1.02
MusicPain ToleranceSilence4.18 kg/cm2Standard Deviation 1
Nature SoundsPain ToleranceAudio5.17 kg/cm2Standard Deviation 0.85
Nature SoundsPain ToleranceSilence5.05 kg/cm2Standard Deviation 0.94
p-value: 0.59Wilcoxon (Mann-Whitney)
p-value: 0.41Wilcoxon (Mann-Whitney)

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026